- Home
- FR vs LEGN Comparison
FR vs LEGN Comparison
Compare FR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FR
- LEGN
- Stock Information
- Founded
- FR 1993
- LEGN 2014
- Country
- FR United States
- LEGN United States
- Employees
- FR N/A
- LEGN N/A
- Industry
- FR Real Estate Investment Trusts
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- FR Real Estate
- LEGN Health Care
- Exchange
- FR Nasdaq
- LEGN Nasdaq
- Market Cap
- FR 6.5B
- LEGN 5.4B
- IPO Year
- FR 1994
- LEGN 2020
- Fundamental
- Price
- FR $49.13
- LEGN $34.00
- Analyst Decision
- FR Buy
- LEGN Strong Buy
- Analyst Count
- FR 11
- LEGN 12
- Target Price
- FR $55.91
- LEGN $77.09
- AVG Volume (30 Days)
- FR 1.1M
- LEGN 2.0M
- Earning Date
- FR 07-16-2025
- LEGN 08-08-2025
- Dividend Yield
- FR 3.64%
- LEGN N/A
- EPS Growth
- FR N/A
- LEGN N/A
- EPS
- FR 2.01
- LEGN N/A
- Revenue
- FR $685,884,000.00
- LEGN $728,303,000.00
- Revenue This Year
- FR $9.72
- LEGN $65.49
- Revenue Next Year
- FR $7.19
- LEGN $53.76
- P/E Ratio
- FR $24.44
- LEGN N/A
- Revenue Growth
- FR 8.47
- LEGN 112.46
- 52 Week Low
- FR $40.31
- LEGN $27.34
- 52 Week High
- FR $58.17
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- FR 47.84
- LEGN 53.16
- Support Level
- FR $48.48
- LEGN $33.84
- Resistance Level
- FR $49.88
- LEGN $35.29
- Average True Range (ATR)
- FR 0.85
- LEGN 1.96
- MACD
- FR -0.05
- LEGN 0.24
- Stochastic Oscillator
- FR 38.41
- LEGN 52.16
About FR First Industrial Realty Trust Inc.
First Industrial Realty Trust Inc is a real estate investment trust that owns, manages, acquires, sells, develops, and redevelops industrial real estate. Through its fully integrated operating and investing platform, the company provides facilities and customer service to multinational corporations and regional firms that are essential for their supply chains. The company serves a diverse tenant base across various sectors, including e-commerce, logistics, transportation, manufacturing, retail, consumer services, food and beverage, building materials, wholesale goods, health services, and government.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.